Axonics Modulation Technologies
Irvine
California
United States
154 articles about Axonics Modulation Technologies
-
Axonics Stockholders Approve Merger Agreement with Boston Scientific
3/22/2024
Axonics, Inc. announced that its stockholders have voted to adopt Axonics’ merger agreement with Boston Scientific Corporation.
-
Axonics Receives CE Mark Approval for Fourth-Generation Rechargeable Sacral Neuromodulation System
3/14/2024
Axonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, announced that the Axonics R20™ rechargeable sacral neuromodulation system has received CE Mark approval.
-
Boston Scientific Announces Agreement to Acquire Axonics, Inc.
1/8/2024
Boston Scientific Corporation announced it has entered into a definitive agreement to acquire Axonics, Inc., a publicly traded medical technology company primarily focused on the development and commercialization of differentiated devices to treat urinary and bowel dysfunction.
-
Axonics Reports Preliminary 4Q23 and Fiscal Year 2023 Revenue
1/8/2024
Axonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, reported preliminary unaudited revenue for the fourth quarter and fiscal year ended December 31, 2023.
-
Axonics Announces Definitive Agreement to be Acquired by Boston Scientific
1/8/2024
Axonics, Inc. announced that it has entered into a definitive agreement to be acquired by Boston Scientific Corporation for $71 in cash per share, representing an equity value of approximately $3.7 billion.
-
Axonics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
12/27/2023
Axonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to present at the J.P. Morgan Healthcare conference at 5:15 p.m. Pacific Time on Monday, January 8, 2024.
-
Axonics to Report Third Quarter 2023 Financial Results on October 30
10/2/2023
Axonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to report third quarter 2023 financial results after the close of trading on Monday, October 30.
-
Axonics to Participate in September 2023 Investor Conferences
8/25/2023
Axonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to participate in the following investor conferences in September.
-
Axonics Announces CFO Retirement and Appoints Successor
8/21/2023
Axonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, announced that Dan L. Dearen, president and chief financial officer, is retiring from the company.
-
Axonics to Report Second Quarter 2023 Financial Results on July 27
6/29/2023
Axonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will report second quarter 2023 financial results after the close of trading on Thursday, July 27.
-
Axonics Reports First Quarter 2023 Financial Results
5/1/2023
Axonics, Inc. reported financial results for the three months ended March 31, 2023.
-
Axonics to Participate in Upcoming May 2023 Investor Conferences
4/25/2023
Axonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to participate in the following upcoming investor conferences: Event.
-
Axonics to Report First Quarter 2023 Financial Results on May 1
4/10/2023
Axonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to report first quarter 2023 financial results after the close of trading on Monday, May 1.
-
Axonics to Participate in the SUFU 2023 Winter Meeting
3/7/2023
Axonics, Inc. is participating as a platinum sponsor of the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction 2023 Winter Meeting, which is being held in Nashville from March 7-11.
-
Axonics Receives FDA Approval for Fourth-Generation Rechargeable Sacral Neuromodulation System
1/31/2023
Axonics, Inc. today announced that the U.S. Food and Drug Administration has approved the company’s fourth-generation rechargeable sacral neuromodulation system.
-
Axonics Reports Preliminary Fiscal Year 2022 Revenue and Provides Fiscal Year 2023 Revenue Guidance
1/11/2023
Axonics, Inc reported preliminary unaudited revenue for the fiscal year ended December 31, 2022 and issued fiscal year 2023 revenue guidance.
-
Axonics® to Participate in the Piper Sandler Healthcare Conference
11/18/2022
Axonics, Inc. will participate in the Piper Sandler Healthcare Conference on December 1, 2022.
-
Axonics® to Report Third Quarter 2022 Financial Results on October 31
10/10/2022
Axonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will report third quarter 2022 financial results after the close of trading on Monday, October 31.
-
Axonics® Announces First Patient Implants in Canada With New Recharge-Free Sacral Neuromodulation System
9/8/2022
Axonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, announced the first patient implants in Canada with the Axonics F15™, the company’s newly developed, long-lived, fully recharge-free sacral neuromodulation system.
-
Axonics® to Participate in September 2022 Investor Conferences
8/18/2022
Axonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, announced that senior management is scheduled to present at the following investor conferences.